TAVOELITE
Current medical therapy is not without problems. Commonly used small molecule and antibody drugs both have multiple limitations.
There are several limitations of small molecule drugs:
-
Small surface area exposure can limit binding affinity and specificity
-
Poor modulation of protein-protein Interactions; Most designs cannot incorporate avidity or allosteric modulation
-
Need for optimizing ADME
Meanwhile, there are also multiple limitations of antibody biologics as well:
-
Biophysical properties prevent cell penetration and limit tissue penetration
-
Many uncertainties in the drug product CMC and immunogenicity
-
Manufacturing process complexity and high cost
To respond to this unmet medical need, Tavotek has created TavoELITE, a novel platform that goes after intracellular targets for the treatment of cancer and other diseases.
Features
-
Enhanced target cell-specific internalization
-
Efficient endosomal escape for intracellular target
-
Intracellular target intervention by protein-protein interaction (modulation, inhibition or degradation) and/or through RNA modulation (silencing or delivering)
Building Blocks
-
Novel molecular constructs that enhance target cell-specific internalization (e.g., VHO and VHO-Fc)
-
CPP, EDD, circular RNA, etc. that enable efficient endosomal escape
-
Utilizing enhanced Fc function or by conjugating small molecule engager to enable ubiquitin protease-mediated degradation
-
Fab, scFv, peptide, or small molecule that specifically interact with the intracellular protein target
-
Shuttled gene therapy components